Furthermore, increasing number of emergency cases and demand for short stay ambulatory day care surgical procedure are amongst critical success factors attributed to the market growth. Access to universal health insurance coverage for a wider population base coupled with constant improvements in healthcare infrastructure in various developing countries are expected to positively impact the number of surgeries performed, thus increasing the usage of inhalation anesthetics.
In-Depth research report on Inhalation Anesthesia market:
https://www.radiantinsights.com/research/inhalation-anesthesia-market
On the basis of product, the inhalation anesthesia market is classified into sevoflurane, isoflurane, and desflurane. These products are used for induction and maintenance of anesthesia for patients during surgical procedures. Sevoflurane led the product segment in 2018 and is anticipated to grow at a lucrative rate over the forecast period, attributed to its therapeutic advantages, low cost, and higher potency for the induction of anesthesia. On the other hand, isoflurane is expected to witness the fastest CAGR of 6.3% over the forecast period, due to its increasing use in maintenance of anesthesia for treatment of weak or geriatric patients owing to its sparing effect on cardiovascular function.
On the basis of regions, the market is broadly classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa (MEA). North America held the leading market share of USD 456.0 million and is anticipated to witness lucrative CAGR over the forecast period. This is owing to increasing prevalence of chronic diseases coupled with the presence of advanced healthcare facilities. On the other hand, Asia Pacific was anticipated to witness the fastest CAGR of 4.0% due to increasing population and number of patients suffering from chronic population.
Some of the key players operating in this market include Halocarbon Products Corporation; Baxter; Hikima Pharmaceuticals PLC; Lunan Pharmaceutical Group Co. Ltd.; Piramal Enterprises Limited; Jiangsu Hengrui Medicine Co. Ltd.; Fresenius Kabi AG, and AbbVie Inc.
Further key findings from the report suggest:
• Sevoflurane product segment led the market in terms of revenue, valued at USD 768.6 million, in 2018
• Isoflurane product segment is anticipated to expand at the fastest CAGR of 6.3% owing to its increasing use in the treatment of weak and geriatric patients owing to its low effect on cardiovascular function
• North America led the market in 2018 with a revenue of USD 456.0 million owing to the presence of advanced healthcare facilities, strong reimbursement scenario, and prevalence of chronic diseases
• Key players operating in the inhalation anesthesia market include Halocarbon Products Corporation; Baxter; Hikima Pharmaceuticals PLC; Lunan Pharmaceutical Group Co. Ltd.; Piramal Enterprises Limited; Jiangsu Hengrui Medicine Co. Ltd.; Fresenius Kabi AG, and AbbVie Inc.
To get free request sample:
https://www.radiantinsights.com/research/inhalation-anesthesia-market/request-sample
Monday, 11 January 2021
Inhalation anesthesia market size is at a lucrative CAGR of 3.5% over the forecast period
Tuesday, 24 November 2020
Global legal marijuana market is anticipated to expand at a CAGR of 18.1%
On the basis of type, the medical segment held the leading revenue share of 71.0% in 2019, owing to the growing adoption of cannabis as a pharmaceutical product for treating severe medical conditions, such as cancer, arthritis, and Parkinson’s disease and Alzheimer’s disease among other neurological conditions. Moreover, increasing need for pain management therapies along with growing disease burden of chronic pain among elders is expected to boost the product demand.
In-Depth research report on Legal Marijuana market:
https://www.radiantinsights.com/research/legal-marijuana-market
Based on product type, the legal marijuana buds segment accounted for the largest market share in terms of revenue and was valued at USD 9.1 billion in 2019. Buds are primary plant products and are readily available without any processing, which makes them relatively affordable for low-income patients. Moreover, the rapid onset of action of smoking buds compared to other types is anticipated to further fuel the segment growth.
Based on medical applications, the chronic pain segment dominated the legal marijuana market in 2019 owing to presence of a large patient pool. On the other hand, mental disorder application is expected to witness the fastest growth over the forecast period owing to the growing number of patients suffering from mental disorders, such as anxiety disorder, depressions, and Alzheimer’s disease.
Based on geography, North America held the largest revenue share at 88.4% in 2019, owing to the increasing legalization of medical marijuana and liberalism of government regulations regarding the same. The legalization of medical cannabis Canada, Israel, and some countries in Europe and South America, owing to its multiple therapeutic applications is expected to promote the growth. Moreover, the recent legalization of cannabis for medical purposes in countries like Australia, Germany, and Poland is expected to create lucrative opportunities for market stakeholders.
Further key findings from the report suggest:
• Based on marijuana type, the medical segment held the largest market share of 71.0% in 2019 owing to the increasing use of the product for the treatment of cancer and other medical conditions
• By product type, the buds segment hold the largest market share in 2019 with a revenue of USD 9.1 billion owing to the easy availability of buds than other products
• Key players operating in the legal marijuana market include Aurora Cannabis; Canopy Growth Corporation; Maricann Group, Inc.; GW Pharmaceuticals, plc.; Aphria, Inc.; Tilray; The Cronos Group; ABcann Medicinals, Inc.; Lexaria Corp.; and Organigram Holding, Inc.
To get free request sample:
https://www.radiantinsights.com/research/legal-marijuana-market/request-sample
Tuesday, 3 November 2020
Growing geriatric population is expected to positively impact the overall market for antacid
Growing geriatric population is expected to positively impact the overall market for antacid. According to the United Nations Department of Economic And Social Affairs (DESA), the global elderly population (60 years and above), was around 962 million in 2017. This number is expected to grow at the fastest rate in Latin America with 71% increase in population aged 60 and over, followed by Asia with 66%, Africa with 64%, North America with 41%, and Europe with 23%.
In-Depth research report on Antacids market:
https://www.radiantinsights.com/research/antacids-market
Key players operating in antacid market focus on product enhancement to cater to patient requirements, such as changing the dosage form into chewable tablets, powder, and jelly. Also, these players are involved in collaborations and acquisitions to expand their market presence. For instance, in 2017, Pfizer, Inc. entered into a strategic agreement with AstraZeneca to acquire one of the antacid brands, Neksium for a value of INR 75 crores in India to boost its product portfolio.
The easy availability of antacids over-the-counter offer growth opportunities for the sales of overall market. Some of the key players areGlaxoSmithKline plc; AstraZeneca; Pfizer, Inc.; Sun Pharmaceuticals Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Bayer AG; Takeda Pharmaceutical Company Limited.
Further key findings from the report suggest:
• In 2017, tablet segment led the antacid market due to high efficacy compared to other dosage forms. Liquid is anticipated to be the fastest growing segment due to its palatable taste and preferred choice for children and elderly population
• Retail pharmacy led the distribution channel segment due its accessibility and availability. Online pharmacy is anticipated to be the fastest growing segment due to growing adoption of Pharma 3.0 and consumer awareness
• Asia Pacific is estimated to be the largest and fastest growing region over the forecast period due to presence of key players such as GlaxoSmithKline plc; Pfizer Inc.; and Abbott among others
• North America held the second largest market share in 2017 owing to increasing prevalence of different digestive disorders
• Some of the key companies operating in this market are GlaxoSmithKline plc; Bayer AG; Boehringer Ingelheim International GmbH; Dr. Reddy's Laboratories Ltd.; Reckitt Benckiser Group plc; Sun Pharmaceuticals Ltd.; Sanofi; Takeda Pharmaceutical Company Limited; Pfizer Inc.; and Procter & Gamble.
To get free request sample:
https://www.radiantinsights.com/research/antacids-market/request-sample
Wednesday, 28 October 2020
Global hemoglobinopathies market is projected to expand at a CAGR of 10.2% during the forecast period
Rising prevalence of hemoglobin disorders such as Sickle Cell Disease (SCD), thalassemia, Hb C, and Hb E is estimated to be a high impact rendering driver for the market. According to the World Health Organization (WHO), hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant hemoglobin variation.
In-Depth research report on Hemoglobinopathies market:
https://www.radiantinsights.com/research/hemoglobinopathies-market
Prevalence of hemoglobinopathies is high in low-income countries from regions, such as Sub-Saharan region and South-east Asia. 85% of the affected population in U.S. and Europe has ancestral base in these regions.
Governments are collaborating with local institutes to undertake awareness programs for curbing the effect of hemoglobinopathies-related mortality rate. For instance, Sickle Cell Disease Coalition (SCDC) was founded by The American Society of Hematology (ASH) in 2016 to promote awareness for the condition and enhance outcomes for individuals.
Insufficient healthcare infrastructure and low levels of disease diagnosis and treatments are some of the key factors contributing to the increase in target population in low-income regions such as South-east Asia, Mediterranean basin, and Africa.
North America led the overall hemoglobinopathies market in terms of revenue in 2018. Growing prevalence of blood disorders, favorable government programs, and high level of awareness among healthcare professionals and patients for hemoglobinopathies-related genetic testing, are the factors attributed to the growth.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to the presence of high unmet clinical needs, improving healthcare infrastructure, and rising economic levels. Moreover, introduction of low-cost diagnostic alternatives for hemoglobinopathies is likely to further boost the growth.
Further key findings from the report suggest:
• SCD segment held the largest market share in 2018 owing to rising prevalence of sickle cell disease and presence of strong product pipeline such as LentiGlobin
• Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. Increasing awareness coupled with rising government programs is anticipated to enhance the usage rates for diagnostic tests pertaining to SCD
• Pre-implant genetic diagnosis is estimated to witness lucrative CAGR of over 8.0% during the forecast period owing to rising awareness levels among the population and increasing healthcare expenditure
• Blood transfusion was the largest therapy segment for hemoglobinopathies, owing to high acceptance of this treatment option and significant success rate
• Key market players include Gamida Cell; Alnylam Pharmaceuticals; Sanofi; Sangamo Therapeutics Inc.; Global Blood Therapeutics; bluebird bio Inc.; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; and Celgene Corporation
To get free request sample:
https://www.radiantinsights.com/research/hemoglobinopathies-market/request-sample
Monday, 21 September 2020
Increasing use of cold plasma in medical treatment and rising cases of HAI are the key driving factors for the global market
September 21, 2020 - The global cold plasma market size is expected to reach USD 198.50 million by 2026 at a strong CAGR of 15.2%. Increasing use of cold plasma in medical treatment and rising cases of Hospital-Acquired Infections (HAI) are the key driving factors for the global market. In healthcare industry, plasma technology has been in use for some time and it continues to help improve various treatments. One of the major properties of cold plasma is the ability to kill bacteria and prevent infection. Therefore, it acts as an effective healing solution. It also accelerates healing process and prevent patient from discomfort.
Cold plasma is used in the treatment of chronic wounds and burns. The bacterial cells, including Multidrug Resistant (MDR) bacteria, are instantly killed after being exposed to cold plasma. As per an article published by the Medical Xpress, Med Tech Europe, around 4.0 million people in Europe suffer from non-healing wounds every year. It also reported that a burn patient in Germany was treated using prototype plasma treatment. Moreover, as per a research published by The National Center for Biotechnology Information (NCBI), a patient suffering with two second-degree burns was treated with cold plasma, which healed the itching and pain and presented new tissue after the second treatment. Such cases are anticipated to promote the usage of cold plasma in various wound treatments.
In-Depth research report on Cold Plasma market:
https://www.radiantinsights.com/research/cold-plasma-market
Further key findings from the study suggest:
• In terms of revenue, atmospheric pressure segment is projected to ascend at the fastest CAGR over the forecast period due to rising application scope in various medical procedures
• Wound healing application segment is expected to witness a significant growth over the forecast period
• Asia Pacific region is estimated to witness the highest growth due to increased adoption of technologically advanced procedures for treatment of various diseases
• Rise in disposable income levels and growing target population base are also likely to contribute to the region's development
• Some of the key companies in the global cold plasma market are U.S. Medical Innovations, LLC, Bovie Medical Corporation, Neoplas Tools GmbH, Europlasma N.V., and P2i Limited.
To get free request sample:
https://www.radiantinsights.com/research/cold-plasma-market/request-sample
Tuesday, 25 August 2020
Biopharmaceutical Third Party Logistics Market - Rsing Demand for Temperature Controlled Logistic Services to Transport Biologics
August 25, 2020 - The global biopharmaceutical third party logistics market size is expected to reach USD 120.64 billion by 2025, at a CAGR 4.9% over the forecast period. The market for biopharmaceutical third party logistics (3PL) is majorly driven by rising demand for temperature controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales. Rising adoption of automated storage and retrieval systems in the emerging countries is an ongoing trend in the pharmaceutical logistics companies that has gained a significant traction.
Furthermore, the trend of shifting from small molecule drugs to biopharmaceuticals, mainly vaccines and biologics, is projected to drive the market. Since, these small molecule drugs are temperature sensitive products, demand for temperature controlled transportation and storage increases and thus is responsible for the market growth. As of now, the pharmaceutical sales through distributors have grown from USD 304.6 billion in 2013 to USD 440.2 billion in 2016. However, the average number of manufacturers per distributor had declined from 1,474 in 2014 to 1,211 in 2016. This data depicts that there is an increase in quantity of pharmaceutical products being distributed, and thus, is expected to surge the demand for 3PL services.
For further inquiries, about Biopharmaceutical Third Party Logistics (3PL) Market
https://www.radiantinsights.com/research/biopharmaceutical-third-party-logistics-3pl-market
Additionally, environmental concerns and cost have caused a slight shift in the means of transport used for commercial product, moving from airway to seaway shipping and in roadways from truck to intermodal (both rail and truck). The intermodal transport is majorly used by these pharmaceutical companies to reduce the carbon footprint. The ongoing trend shows that the pharmaceutical manufacturers have shifted towards sea freight to reduce the cost and risk factor. Although for cold chain products, the companies still prefer air freight. However, some of the large pharmaceutical companies are planning to transport 70% of their products via ocean freight including cold chain products.
Further key findings from the report suggest:
• In 2018, non-cold chain logistics held the largest market share in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control
• Cold chain logistics segment is expected to register the faster CAGR over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits
• Warehousing and storage held the largest market share among the types of services in 2018
• Asia pacific expected to emerge with the fastest CAGR over the forecast period owing to adoption of medicines from aging population and shift of drug sales from brand manufacturers to generic
• Key players operating in the biopharmaceutical third party logistics market include DHL International GmbH., SF Express, United Parcel Service of America, Inc, AmerisourceBergen Corporation, DB Schenker, Kuehne and Nagel, Kerry logistics network limited and Agility.
To get free request sample :
https://www.radiantinsights.com/research/biopharmaceutical-third-party-logistics-3pl-market/request-sample
Monday, 24 August 2020
New Study Projects Strong Growth for Global Telepresence Equipment Market
August 24, 2020 - Telepresence refers to a set of technologies which allow a person to feel as if they were present, to give the appearance of being present, or to have an effect, via telerobotics, at a place other than their true location. In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market.
Telepresence Equipment Report by Material, Application, and Geography - Global Forecast to 2023 is a professional and comprehensive research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).
In-Depth research report on Telepresence Equipment market:
https://www.radiantinsights.com/research/global-telepresence-equipment-market-research-report-2019-2023
In this report, the global Telepresence Equipment market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2023, growing at a CAGR of XX% during the period 2019 to 2023.
The report firstly introduced the Telepresence Equipment basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
The major players profiled in this report include:
- Array telepresence
- Avaya
- Cisco Systems
- Huawei Technologies
- Polycom
- Vidyo
- ZTE Corporation
The end users/applications and product categories analysis:
On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-
- Large Enterprise
- Medium Enterprise
- Small Enterprise
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Telepresence Equipment for each application, including-
- Healthcare
- Education
- Pharmaceuticals
Download free request sample :
https://www.radiantinsights.com/research/global-telepresence-equipment-market-research-report-2019-2023/request-sample
Monday, 27 July 2020
Global hemophilia market size is anticipated to register a CAGR of 5.5% over the forecast period
Browse full research report :
https://www.radiantinsights.com/research/hemophilia-market
For instance, the NHF (National Hemophilia Foundation) allows to find treatments for inheritable bleeding disorders and help prevent complications of these disorders through research, education, and advocacy. Their programs and initiatives are in association with the Centers for Disease Control and Prevention.
In addition, U.S. Hemophilia Treatment Center Network provides specialized healthcare centers and these offer care to address all psychological, educational, and physical needs of patients suffering from the disease. These centers currently provide care to more than 35,000 adults and children with the disease and other bleeding disorders.
The key market companies are projected to adopt strategic initiatives including geographic expansion and R&D especially in developing and underdeveloped regions, such as Middle Eastern and West African countries.
For instance, BioMarin is involved in developing Valoctocogene Roxaparvovec (BMN-270) for treating type A patients and is currently under clinical trials. Furthermore, in June 2017, the U.S. FDA accepted the investigational new drug application for Sanofi’s BIVV001 based on its preclinical study results.
Rising incidence of the disease is estimated to propel hemophilia market growth over the forecast period. According to the data published by the NHF, around 20,000 individuals in U.S. are suffering from this disease. In addition, approximately 75% of people with hemophilia receive inadequate treatment or have less/ no access to treatment globally.
Further key findings from the report suggest:
• Hemophilia A held the largest market share in 2019 due to its increasing prevalence worldwide
• Type B is expected to be the fastest growing type over the forecast period, at a CAGR of 6.8%
• On-demand dominated the treatment segment over the forecast period and is expected to contribute majority of the share in 2019
• Prophylaxis is estimated to be the fastest growing segment over the forecast period
• Replacement therapy was expected to be the largest segment in 2019
• Gene therapy dominated the therapy segment over the forecast period owing to increasing involvement of companies to develop more gene therapy for its treatment
• Increasing research and development and strategic collaborations are key strategies undertaken by major players in the market space.
To get free request sample :
https://www.radiantinsights.com/research/hemophilia-market/request-sample
Thursday, 23 July 2020
Global complementary and alternative medicine market size is projected to reach USD 296.3 billion by 2027
In-Depth research report on Complementary And Alternative Medicine market:
https://www.radiantinsights.com/research/complementary-and-alternative-medicine-market
In addition, increase in the number of licensed and trained physicians who can offer state-of-the-art complementary therapies is set to boost patient preference toward traditional medicine. It is becoming integral in the healthcare system in Asia, especially in China wherein most of the hospitals in the country have distinct departments and wards that are dedicated to traditional therapeutic approaches.
Moreover, in terms of research, CAM has reached a remunerative stage. This can be attributed to the rising pool of scientists working at established universities across U.S., Europe, and Asia Pacific who are focusing on building a robust foundation for the alternative treatment targeted toward Parkinson’s disease, cancer, and diabetes.
Further key findings from the report suggest:
• Botanicals are the most ancient form of alternative treatment practices, which include herbal and natural treatment supplements along with another natural form of treatments incorporating oils, herbs, and other curative supplements
• The botanicals intervention segment dominated the global market throughout the study period, whereas magnetic intervention is expected to grow at the fastest rate from 2020 to 2027
• Mind and body healing oriented traditional medicines are some of the most frequently adopted forms of alternate therapies worldwide. Mind and body intervention incorporates various forms of energy and mind exercises to heal ailments
• Yoga has dominated the global complementary and alternative medicine market throughout the study period, whereas hypnotherapy is projected to witness the highest growth rate over the forecast period
• Europe is anticipated to witness highest market share over the forecast period. Rising preference for alternative treatment approaches among patients will drive the regional market for complementary and alternative medicine.
• Key industry participants include Nordic Nutraceuticals, Pure encapsulations, LLC, AYUSH Ayurvedic Pte Ltd, and Sheng Chang Pharmaceutical Company
• Companies are inclined toward strategic partnerships to establish their presence in the market; for instance, in June 2019, AstraZeneca partnered with Luye Pharma Group to market a herbal therapy
• The herbal medicine product is developed from red yeast rice and is formulated to assist patients suffering from cholesterol. With this partnership, AstraZeneca is set to expand its business across China.
Download free request sample :
https://www.radiantinsights.com/research/complementary-and-alternative-medicine-market/request-sample
Monday, 13 August 2018
Artificial Knee Implants to Alleviate Joint Pain
Browse full research report :
Advent of 3D printing has made it possible to create customized implants according to gender or bone shape and size. Computer assisted surgery (CAS) and robotic assisted surgery are methods gaining prominence by performing successful surgeries and reduce patient recovery rate.
Customized Implants and Robotic Assistance
Types of surgical procedures for artificial knee implants are segmented into partial, total, and revision.
The total knee replacement (TKR) segment is expected to generate bigger revenues compared to its counterparts due to high demand for these surgeries in Germany and U.S. Advances in surgical procedures and their subsequent demand in developing economies are projected to spur segment demand in the forthcoming years. This is exemplified by the 100,000th successful surgery of the Mako System, a robotic assistant, by Stryker Corporation in 2017.
The partial knee replacement (PKR) segment is projected to gain good returns due to increasing incidence of unicompartmental knee osteoarthritis (UKOA). Improvements in implant designs and utilization of robots to increase surgical outcomes can augur segment demand in the forthcoming years. In 2017, Zimmer Biomet Holdings launched the Persona Partial Knee System to cater to patients demand for personalized implants.
Market Outlook
The artificial knee implant market is set to expand at a phenomenal growth rate in the forthcoming years, as per a report on Radiant Insights, Inc. Rise in market demand can be attributed to the growing geriatric populace, preference of minimally invasive surgeries (MIS), and prevalence of arthritis. Increasing investments in the healthcare sector in China and India can open up new opportunities for players in the near future. Price caps placed on knee implants in developing economies can lead to its implementation in hospitals. Key market players include B. Braun Melsungen AG; Zimmer Biomet Holdings, Inc.; Stryker Corporation; and Smith & Nephew plc.
Tuesday, 12 June 2018
Enhancing Hearing Ability Hybrid Cochlear Implant
Read full research report :
User Friendly and Efficient Solutions
The technology is ideal for adults as well as pediatrics patients suffering from hearing defects. Adults segment has been dominating the market in the recent past. This can be attributed due to existence of huge patient base and less complications involved as compared to pediatric patients. The technology can become a feasible choice for elder patient who failed to get hearing benefit from other wearing hearing aids.
The pediatric segment is likely to show rapid growth over the forecast period. Growing need for solutions to treat pediatrics patients due to increasing number of cases in of hearing defects in newborns can boost demand. According to worlds health organization (WHO), every year almost, 134 million kids are born, out of which around one or three neonates per thousand are recorded to have hearing defects. This will increase the need for advanced hearing aids in the years to come. Technological development in hearing devices, especially for child patients can also drive the growth for the segment.
For Instance, Cochlear Limited, a provider of implantable hearing solutions recently introduced the new Cochlear Baha SoundArc in the US and Canada. The product can be an effective as well as stylish wearing option for children with conductive hearing loss, mixed hearing loss or single-sided sensorineural deafness (SSD).
Market Overview
According to a report available on Radiant Insights, Inc., the hybrid cochlear implant market is likely to show significant growth through 2022. Factors like increasing old age population worldwide, increasing government backing and satisfactory reimbursement policies, growing awareness about hearing aids, and technological improvements in devices can propel the market over the forecast period (2018 to 2022).
Europe is one of the largest markets due to presence of huge number of patients in the region and conductive healthcare infrastructure that allows implantation of device at early age.
Leading players operating in the market include Nurotron Biotechnology Co. Ltd., William Demant Holding A/S; Cochlear Ltd., and Nurotron Biotechnology Co. Ltd.
Wednesday, 16 May 2018
Scandium: A Potential Substitute for Rare Earth Elements like Yttrium
Read full research report : www.bit.ly/2IMBMb1
Electronics to be the Major Application Segment
The electronics segment is anticipated to witness rapid growth as it is a major consumer of scandium metals. Some lasers use GSGG (Gadolinium Scandium Gallium Garnets). In addition, scandium is used in various high performance switches in computers. All these factors are predicted to have a huge impact on the global demand for scandium over the forecast years i.e., from 2017 to 2022.
The LED and laser segment is also estimated to have a substantial growth over the coming years. The key factor responsible for the development of this segment includes the extensive usage of scandium for manufacturing high-intensity lights and bulbs, that imitate natural sun light or day light. The valuable metal has a wide emission spectrum, which is close enough to sunlight and used in television and movie studio lighting and camera lighting systems for greater and natural effects.
Market Overview
As suggested by the findings of a recent report made available by Radiant Insights, Inc.; the worldwide scandium market would develop at a significant annual CAGR of 6.3 % over the forecast period. Extensive usage of scandium in solid oxide fuel cells (SOFCs) and rising demand from the automotive and aerospace sectors are projected to augment market growth over the coming years. The leading players in this market include Scandium International Mining Corp.; Guangzhou CNMC (GUANGXI) PGMA Co. Ltd.; Changsha Asian Light Economic Trade Co. Ltd.; and Baotou Lanthanide New Material Technology Co. Ltd. Mergers and acquisitions (M&A) activities and partnerships are key strategies followed by most of these players.
For instance, Clean TeQ Holdings Ltd. has signed a deal with Chongqing University and Chinalco Materials Application Research Institute (CMRI) for the development of scandium-containing alloys for the global transportation industry. This partnership will bring together various production and research engineers from the Chongqing University, CMRI, and Clean TeQ for developing and commercializing the next generation of advanced scandium alloys for aerospace and automobile sectors.
Tuesday, 17 October 2017
FDA Approves New Add-on Parkinson’s Disease Drug
Common symptoms of the disease include:
- Fatigue
- Slow bodily movements
- Co-ordination problems
- Little or no facial expressions
- Poor balance
- Difficulty walking
- Difficulty thinking and understanding
- Impaired voice
- Amnesia
The Parkinson’s disease drugs market, at present, has great scope for growth owing to high unmet clinical needs resulting from lack of Disease Modifying Drugs (DMDs). Thus, many key players are focusing on research and development activities and clinical trials along with novel product launches. This may augment the growth of the market in future.
Recently, Newron Pharmaceuticals SpA received FDA approval for Xadago (safinamide) for the treatment of Parkinson’s disease. The effectiveness of Xadago in treating the disease was shown in a clinical trial of a group of patients. This study was conducted on patients who were taking levodopa and were having “off” time, where a patient’s medicines stop working, further aggravating disease symptoms.
The study showed that patients taking Xadago had more “on” time, where disease symptoms are reduced, without any involuntary uncontrolled movements.
Market Overview
As per the findings of a new study made available by Radiant Insights, Inc., the worldwide Parkinson’s disease drugs market is anticipated to witness strong growth during the forecast period (from 2017 to 2021). Increasing geriatric population across the world is expected to drive the growth of the global market over the next few years. Moreover, many firms, such as International Stem Cell Corp., are focusing on clinical trials for stem cell therapies for the treatment of Parkinson’s. Hence, this therapy is likely to provide significant growth prospects for the development of the global market.
Teva Pharmaceutical Industries Ltd.; Salix Pharmaceuticals, Inc.; Impax Laboratories, Inc.; Orion Corp.; Novartis International AG; and GlaxoSmithKline PLC. are some of the prominent firms operating in the global Parkinson’s disease drugs market.
Wednesday, 11 October 2017
Nuclear Medicine Enables Easy and Painless Diseases Diagnosis and Treatment
Browse full research report at: https://goo.gl/29Q7Ek
Recent Innovations in Nuclear Medicine
Value-based care has changed the way healthcare companies provide care delivery, thereby increasing the need for faster, user-friendly, and accurate imaging technologies. With molecular imaging doctors can make accurate decisions based on the particular cellular and molecular patterns of a disease.
Royal Philips recently launched their latest solutions and technologies that may drive the future of nuclear medicine.
- Vereos Digital PET/CT
Market Overview
Growing cases of various chronic diseases across the world are anticipated to augment growth of the global nuclear medicine market over the forecast period (from 2017 to 2021). Factors such as increased awareness, technological advancements, and abundance of radiotracers or radiopharmaceuticals are also estimated to fuel the demand over the years to come.
Moreover, need for precise and quick diagnostic processes and increased demand for advanced therapies are also projected to boost the global market. Some of the key companies in the worldwide market include Eckert & Ziegler Group; GE Healthcare; Bracco Imaging S.p.A.; Siemens Healthineers; and Toshiba Medical Systems Corp.
Friday, 8 September 2017
How Do Cardiac Catheters Regulate Pumping of Heart?
What are Cardiac Catheters?
These medical devices are used to diagnose heart conditions by inserting them into heart chambers. Different types of cardiac catheters include bipolar pacing pins, angiographic balloons, hexapolar balloon pacing, semi flotating electrodes, thermodilution infusion, wedge pressure catheter, and others. These products are used for different types of cardiac diseases.
Substitute to Bypass Surgery
Recently, Medtronic received approval from the U.S. Food & Drug Administration (FDA) for its CoreValve Evolut PRO valve. This device is useful for the treatment of aortic stenosis. It is designed for positioning accuracy during the transcatheter aortic valve replacement (TAVR). This minimally invasive surgery can avoid the need for open heart surgery.
Market Overview
According to a report available on Radiant Insights, Inc.; high prevalence of cardiovascular diseases can drive the cardiac catheters market by 2021. Increasing geriatric population can further propel the market over the forecast period (2017 to 2021).
Angiographic balloon catheters may display significant growth in the near future due to rising demand for interventional catheterization. Transcatheter aortic valve implantation (TAVI) or TAVR applications may also show lucrative growth in the forthcoming years due to high adoption of minimally invasive surgeries.
North America may continue dominating the market on account of demand over the forecast period. High number of cardiac surgeries is considered as the key regional driver. Asia Pacific on the other hand, is anticipated to grow rapidly owing to developing healthcare facilities in India and China. Europe may showcase considerable growth due to establishment of cardiac cath labs for quick diagnosis of cardiovascular disorders.
Major companies operating in the market include Boston Scientific Corporation, Abbott Laboratories, Medtronic Public Limited Company (plc), and Maquet.
Global and Chinese Cardiac Catheters Industry -
Tuesday, 8 August 2017
Antiviral Drugs Market Region, Service and Outlook to 2025
The global antiviral drugs market is expected to reach a value of USD 69.2 billion by 2025, based on a new report by Grand View Research, Inc. According to the WHO, cases of viral infections increase by more than 1 million each year with around 357 million patients already suffering from one of the four Sexually Transmitted Infections (STIs), such as Acquired Immunodeficiency Syndrome (AIDS).
For instance, Gilead Sciences introduced an FDA-approved drug-Genvoya-in 2016 for treatment of AIDS patients who have previously faced adverse effects, such as bone loss and kidney dysfunction.
Low levels of hygiene, growing geriatric population, and increasing awareness through government campaigns are other drivers resulting in high acceptance of antiviral drugs in developing countries.
Further Key Findings from the Study Suggest:
- Reverse transcriptase inhibitors held the largest share by mechanism of action owing to availability of wide range of product portfolio and presence of new molecules in clinical trials
- Nucleotide inhibitors are estimated to grow at lucrative rate due to introduction of blockbuster molecules for treatment of Hepatitis C Virus (HCV) infections
- Generic drugs are anticipated to witness significant CAGR of over 7.0% over the forecast period as result of patent expiry of blockbuster drugs used for treatment of HIV and HCV
- Branded drugs will hold dominant position in 2025 by drug type due to brand loyalty of healthcare professions despite patent expiration and high price associated with these molecules
- HIV/AIDS held the dominant share in 2015. High prevalence of HIV infections and presence of favorable government initiatives for curbing them are key factors for high revenue of this segment
- Hepatitis on the other hand is anticipated to witness flourishing growth over the forecast period owing to introduction of new molecules and approval of novel combination treatments
- North America was the dominant regional market in 2015. High market share is associated with established R&D infrastructure and growing drug development initiatives
- Asia Pacific region is anticipated to exhibit fastest regional growth. Local presence of key generic players and growing healthcare infrastructure in this region are key factors for growth
- Some of the key players of this market include Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline; Bristol-Myers-Squibb; AbbVie; Johnson & Johnson; and Merck & Co. Other generic players in this market are Aurobindo Pharma, Cipla, and Dr Reddy's
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Antiviral Drugs Market Variables, Trends & Scope
3.1 Market segmentation& scope
3.2 Penetration & growth prospect mapping
3.3 Antiviral Drugs- SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter's
Contact:
Michelle Thoras
Radiant Insights, Inc
San Francisco, CA 94105
Phone: 1-415-349-0054
Toll Free: 1-888-928-9744
Email: sales@radiantinsights.com
Web: www.radiantinsights.com
Animal Health Market Strategies, Share and Size to 2025
For instance, MediLabSecure, a laboratory network project, was initiated with an aim of identifying emerging viruses and pathogens in 19 countries in the Mediterranean regions. In addition, emergence of veterinary health information systems, specifically in the developed economies, is expected to provide high growth potential in future.
With the help of these systems, data generated in veterinary clinics can be uploaded on the internet, which can be further shared with other researchers and clinicians. The incorporation of this technology will facilitate real-time analysis of fluctuations in disease prevalence. As a consequence of the aforementioned factors, it is presumed that there will be significant improvement in the overall penetration rate of animal health products, which is also anticipated to fuel the market demand as well as the revenue to unprecedented heights.
Further Key Findings from the Study Suggest:
- Vaccines are expected to exhibit lucrative growth rate during the forecast period. The exponential growth can be attributed to significant increase in the companion animal population, which demands long-term health
- Companion animal segment is anticipated to grow at an exponential rate owing to is a consequence of associated health benefits for humans, which includes lower blood pressure, greater psychological stability, and reduced anxiety attacks
- In 2015, North America accounted for the largest share in the global animal health market owing to local presence of established pharmaceutical companies, consistently striving for extensive commercialization of their products
http://www.radiantinsights.com/research/animal-health-market/request-sample
- Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of high clinical urgency to curb high incidence of zoonotic diseases and management of disease outbreaks, such as swine influenza and Ebola
- The key participants employ sustainability strategies, such as expanding product portfolio to gain competitive advantage. For instance, In March 2016, Merial entered into distribution agreement with Zoetis, Inc. to expand the dairy product portfolio in India